{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T04:54:43Z","timestamp":1758862483314},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite increasing effort for treating primary central nervous system lymphoma (PCNSL), the prognosis of human immunodeficiency virus (HIV) -related PCNSL was still unsatisfactory. There is currently a lack of clinical evidence for the application of Bruton tyrosine kinase (BTK) inhibitor in HIV-related PCNSL. We reported two HIV-related PCNSL patients, who achieved sustained remission by application of BTK inhibitor based treatment. This protocol had not been previously reported for the treatment of HIV-related PCNSL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>The two cases were characterized by the treatment choice of Bruton tyrosine kinase (BTK) inhibitor. Rituximab was not recommended for them due to their very low CD4<jats:sup>+<\/jats:sup> T cell counts. They both took MTX as the first-line therapy and got a relief in initial phase. For the first case, ibrutinib was kept both in the first-line therapy and in the maintenance therapy. When the second case underwent a progressive disease, we continued to use orelabrutinib as one of the salvage treatment, in combination with programmed cell death-1 (PD-1) inhibitor plus lenalidomide. They both achieved a continuous response of up to 20 months without opportunistic infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This report highlights the safety and effectiveness of BTK inhibitors, as well as lenalidomide and PD-1 inhibitor in HIV-related PCNSL patients. Both the new therapeutic approaches and a multidisciplinary team authentically contributed to improved survival outcome among HIV-positive PCNSL patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12981-023-00554-8","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T13:03:04Z","timestamp":1693314184000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Ying","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuyong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"key":"554_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/B978-0-444-63849-6.00014-1","volume":"152","author":"D Brandsma","year":"2018","unstructured":"Brandsma D, Bromberg JEC. Primary\u2002CNS\u2002lymphoma\u2002in\u2002HIV\u2002infection Handb Clin Neurol. 2018;152:177\u201386.","journal-title":"Primary\u2002CNS\u2002lymphoma\u2002in\u2002HIV\u2002infection Handb Clin Neurol"},{"issue":"9","key":"554_CR2","doi-asserted-by":"publisher","first-page":"e641","DOI":"10.1016\/S2352-3018(20)30118-1","volume":"7","author":"SM Kimani","year":"2020","unstructured":"Kimani SM, Painschab MS, Horner MJ, Muchengeti M, Fedoriw Y, Shiels MS, et al. Epidemiology of haematological malignancies in people living with\u2002HIV. Lancet HIV. 2020;7(9):e641\u201351.","journal-title":"Lancet HIV"},{"issue":"48","key":"554_CR3","doi-asserted-by":"publisher","first-page":"e31793","DOI":"10.1097\/MD.0000000000031793","volume":"101","author":"X Ding","year":"2022","unstructured":"Ding X, Liang T, Liang B, Gao H, Wang J, Liu H, et al. Diagnostic value of EBV-DNA in CSF for PCNSL in AIDS patients with focal brain lesions: a meta-analysis of diagnostic test. Med (Baltim). 2022;101(48):e31793.","journal-title":"Med (Baltim)"},{"issue":"3","key":"554_CR4","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/jha2.474","volume":"3","author":"C Dittus","year":"2022","unstructured":"Dittus C, Grover N, Sethi T, Cohen JB, Voloschin A, Rabadey J, et al. A multicenter, real-world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus. EJHaem. 2022;3(3):734\u20138.","journal-title":"EJHaem"},{"issue":"2","key":"554_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11060-010-0252-3","volume":"101","author":"S Bayraktar","year":"2011","unstructured":"Bayraktar S, Bayraktar UD, Ramos JC, Stefanovic A, Lossos IS. Primary\u2002CNS lymphoma\u2002in\u2002HIV\u2002positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol. 2011;101(2):257\u201365.","journal-title":"J Neurooncol"},{"issue":"8","key":"554_CR6","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1212\/WNL.0000000000004265","volume":"89","author":"A Moulignier","year":"2017","unstructured":"Moulignier A, Lamirel C, Picard H, Lebrette MG, Amiel C, Hamidi M, et al. Long-term\u2002AIDS-related\u2002PCNSL\u2002outcomes\u2002with\u2002HD-MTX\u2002and\u2002combinedantiretroviral\u2002therapy. Neurology. 2017;89(8):796\u2013804.","journal-title":"Neurology"},{"issue":"19","key":"554_CR7","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1182\/blood.2020006048","volume":"136","author":"K Lurain","year":"2020","unstructured":"Lurain K, Uldrick TS, Ramaswami R, Polizzotto MN, Goncalves PH, Widell A, et al. Treatment\u2002of\u2002HIV-associated\u2002primary\u2002CNS\u2002lymphoma\u2002with\u2002antiretroviral therapy, rituximab, and high-dose methotrexate. Blood. 2020;136(19):2229\u201332.","journal-title":"Blood"},{"issue":"21","key":"554_CR8","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.3390\/cancers13215372","volume":"13","author":"LR Schaff","year":"2021","unstructured":"Schaff LR, Grommes C. Update on Novel therapeutics for\u2002primary\u2002CNS lymphoma. Cancers (Basel). 2021;13(21):5372.","journal-title":"Cancers (Basel)"},{"key":"554_CR9","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/EDBK_242547","volume":"39","author":"AJM Ferreri","year":"2019","unstructured":"Ferreri AJM, Holdhoff M, Nayak L, Rubenstein JL. Evolving\u2002treatments\u2002for primary\u2002Central\u2002Nervous\u2002System\u2002Lymphoma. Am Soc Clin Oncol Educ Book. 2019;39:454\u201366.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"21","key":"554_CR10","doi-asserted-by":"publisher","first-page":"5534","DOI":"10.3390\/cancers13215534","volume":"13","author":"M Verdu-Bou","year":"2021","unstructured":"Verdu-Bou M, Tapia G, Hernandez-Rodriguez A, Navarro JT. Clinical and therapeutic implications of Epstein-Barr Virus in HIV-Related Lymphomas. Cancers (Basel). 2021;13(21):5534.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"554_CR11","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/CCO.0b013e32834b6adc","volume":"23","author":"A Gonz\u00e1lez-Aguilar","year":"2011","unstructured":"Gonz\u00e1lez-Aguilar A, Soto-Hern\u00e1ndez JL. The\u2002management\u2002of\u2002primary\u2002central nervous\u2002system\u2002lymphoma\u2002related\u2002to AIDS\u2002in the HAART era. Curr Opin Oncol. 2011;23(6):648\u201353.","journal-title":"Curr Opin Oncol"},{"key":"554_CR12","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","volume":"129","author":"L Nayak","year":"2017","unstructured":"Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, et al. PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129:3071\u20133.","journal-title":"Blood"},{"issue":"2","key":"554_CR13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/10428194.2018.1480771","volume":"60","author":"P Ambady","year":"2019","unstructured":"Ambady P, Szidonya L, Firkins J, James J, Johansson K, White T, et al. Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma. Leuk Lymphoma. 2019;60(2):515\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"554_CR14","doi-asserted-by":"publisher","first-page":"8676","DOI":"10.1002\/cam4.3499","volume":"9","author":"FL Chen","year":"2020","unstructured":"Chen FL, Pang DW, Guo HG, Ou QX, Wu X, Jiang XM. Clinical outcomes of newly diagnosed primary CNS lymphoma lymphoma treated with ibrutinib-based combination therapy: a real-world experience of off-label ibrutinib use. Cancer Med. 2020;9(22):8676\u201384.","journal-title":"Cancer Med"},{"issue":"S1","key":"554_CR15","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1182\/blood-2021-150658","volume":"138","author":"XX Wang","year":"2021","unstructured":"Wang XX, Gao Y, Yu SS, Bai B, Ou QX, Zhu LQ, et al. Preliminary results of a phase II study of methotrexate in combination with ibrutinib and temozolomide (MIT) in newly diagnosed primary CNS lymphoma. Blood. 2021;138(S1):2481\u20133.","journal-title":"Blood"},{"key":"554_CR16","doi-asserted-by":"publisher","first-page":"901797","DOI":"10.3389\/fonc.2022.901797","volume":"12","author":"C Yang","year":"2022","unstructured":"Yang C, Cui Y, Ren X, Li M, Yu K, Shen S, et al. Orelabrutinib combined with lenalidomide and immunochemotherapy for Relapsed\/Refractory primary central nervous system lymphoma: a retrospective analysis of case series. Front Oncol. 2022;12:901797.","journal-title":"Front Oncol"},{"key":"554_CR17","doi-asserted-by":"crossref","unstructured":"Wu JJ, Wang WH, Dong M, Ma SS, Zhang XD, Zhu LN Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: A retrospective study. Invest New Drugs. 2022;40(3):650\u20139.","DOI":"10.1007\/s10637-022-01219-5"},{"key":"554_CR18","doi-asserted-by":"crossref","unstructured":"Tsuyuki Y, Ishikawa E, Kohno K, Shimada K, Ohka F, Suzuki Y, et al. Expression of programmed cell death ligand-1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large B-celllymphoma of the central nervous system. Neuropathology. 2021;41(2):99\u2013108.","DOI":"10.1111\/neup.12705"},{"key":"554_CR19","doi-asserted-by":"crossref","unstructured":"Monabati A, Nematollahi P, Dehghanian A, Safaei A, Sadeghipour A, Movahedinia S, et al. Immune Checkpoint Molecules in\u2002primary\u2002diffuse large B-Cell\u2002lymphoma\u2002of the\u2002Central\u2002Nervous\u2002System. Basic Clin Neurosci. 2020;11(4):491\u20138.","DOI":"10.32598\/bcn.11.4.2542.1"},{"key":"554_CR20","doi-asserted-by":"crossref","unstructured":"Sugita Y, Furuta T, Ohshima K, Komaki S, Miyoshi J, Morioka M et al. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: the role of programmed cell death 1 and programmed cell death ligand 1.Neuropathology.2018;38(2):125\u201334.","DOI":"10.1111\/neup.12435"},{"key":"554_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"C Soussain","year":"2019","unstructured":"Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, et al. Ibrutinib mono-therapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II \u2018proof-of-concept\u2019 iLOC study by the Lymphoma study association (LYSA) and the french oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019;117:121\u201330.","journal-title":"Eur J Cancer"},{"issue":"9","key":"554_CR22","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","volume":"7","author":"C Grommes","year":"2017","unstructured":"Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, et al. Ibrutinib unmasks critical role of Bruton Tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7(9):1018\u201329.","journal-title":"Cancer Discov"},{"key":"554_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"C Soussain","year":"2019","unstructured":"Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II \u2018proof-of-concept\u2019 iLOC study by the Lymphoma study association (LYSA) and the french oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019;117:121\u201330.","journal-title":"Eur J Cancer"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-023-00554-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-023-00554-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-023-00554-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T03:42:57Z","timestamp":1700278977000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-023-00554-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["554"],"URL":"https:\/\/doi.org\/10.1186\/s12981-023-00554-8","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"7 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient has provided written informed consent for the publication of this report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}